Zacks Research Downgrades Curaleaf (OTCMKTS:CURLF) to Hold

Curaleaf (OTCMKTS:CURLF) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Curaleaf Price Performance

Shares of OTCMKTS:CURLF opened at $3.64 on Wednesday. The company has a quick ratio of 0.74, a current ratio of 1.56 and a debt-to-equity ratio of 1.05. Curaleaf has a fifty-two week low of $0.72 and a fifty-two week high of $5.05. The firm has a 50-day simple moving average of $3.08 and a 200 day simple moving average of $2.71. The company has a market cap of $2.54 billion, a PE ratio of -28.00 and a beta of 1.53.

Curaleaf (OTCMKTS:CURLF) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.51. Curaleaf had a negative net margin of 7.76% and a negative return on equity of 8.11%. The business had revenue of $324.23 million during the quarter, compared to the consensus estimate of $316.62 million. On average, sell-side analysts anticipate that Curaleaf will post -0.1 EPS for the current year.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.